Catalog |
name |
Description |
price |
R-R-2923 |
GRK5-IN-2 CAS No.1642839-27-7 |
GRK5-IN-2 (compound 707)/CAS No.1642839-27-7, a pyridine-based bicyclic compound, is a potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor. GRK5-IN-2 regulates the expression and/or release of insulin and is useful for the metabolic disease research. |
price> |
R-R-2924 |
CCG258208 hydrochloride |
CCG258208 (GRK2-IN-1) hydrochloride is a potent and selective GRK2 (G protein-coupled receptor kinase 2) inhibitor (IC50=30 nM) while maintaining 230-fold selectivity over GRK5 (IC50=7.09 μM) and more than 2500-fold selectivity over GRK1 (IC50=87.3 μM), PKA, and ROCK1. CCG258208 hydrochloride can be used in heart failure research. |
price> |
R-R-2925 |
GRK6-IN-2 CAS No.2677786-27-3 |
GRK6-IN-2 (compound 10a)/CAS No.2677786-27-3 is a potent inhibitor of G protein-coupled receptor kinase 6 (GRK6) with an IC50 of 120 nM. GRK6 is a critical kinase required for the survival of multiple myeloma (MM) cells. GRK6-IN-2 has the potential for the research of multiple myeloma. |
price> |
R-R-2926 |
CCG273441 CAS No.2750414-35-6 |
CCG273441/CAS No.2750414-35-6 is a covalent inhibitor of G protein-coupled receptor (GPCR) kinase 5 (GRK5) with an IC50 value of 3.8 nM. CCG273441 is highly selective to GRK5 over GRK2 (IC50=4.8 μM) by binding Cys474, a GRK5 subfamily-specific residue, as a covalent handle. |
price> |
R-R-2927 |
KR-39038 CAS No.2770300-35-9 |
KR-39038/CAS No.2770300-35-9 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research. |
price> |
R-R-2928 |
GRK2i TFA |
GRK2i TFA is a GRK2 inhibitory polypeptide that specifically inhibits Gβγ activation of GRK2. GRK2i TFA corresponds to the Gβγ-binding domain and acts as a cellular Gβγ antagonist. |
price> |
R-R-2929 |
Lificiguat CAS No.170632-47-0 |
Lificiguat/CAS No.170632-47-0 binds to the β subunit of soluble guanylyl cyclase(sGC) with Kd of 0.6-1.1 μM in the presence of CO. |
price> |
R-R-2930 |
Vericiguat CAS No.1350653-20-1 |
Vericiguat (BAY1021189)/CAS No.1350653-20-1 is a potent, orally available and soluble guanylate cyclase stimulator. |
price> |
R-R-2931 |
Linaclotide CAS No.851199-59-2 |
Linaclotide/CAS No.851199-59-2 is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation. |
price> |
R-R-2932 |
Cinaciguat CAS No.329773-35-5 |
Cinaciguat/CAS No.329773-35-5 is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure. |
price> |